Spotlight Medical Secures IVDR CE Marking for myStage Dx, Its AI-Enabled Prognostic Test for ER+/HER2 – Early Breast Cancer
Spotlight Medical, a Paris-based oncology diagnostics company, today announced that myStage Dx has received CE marking under the European Union In Vitro Diagnostic Medical Devices Regulation (IVDR, Regulation (EU) 2017/746).
Spotlight Medical Announces Publication in Journal of Clinical Oncology Validating AI Pathology Assay That Identifies Low-Risk Subgroup Within Clinically High-Risk Early ER+/HER2- Breast Cancer
Spotlight Medical today announced that the Journal of Clinical Oncology has published a peer-reviewed study describing a clinicopathologic assay that identifies a sizeable subgroup of patients labelled clinical high risk (ER-positive, HER2-negative early breast cancer) who have a favourable long term prognosis after standard chemo-endocrine therapy alone. The study reports blinded validation on two prospective cohorts from the CANTO and UNIRAD trials.
Spotlight Medical Secures €6.2M in Seed Funding to Enhance Cancer Treatment Strategies with AI-Powered Prognosis Tests
Spotlight Medical, a pioneering startup developing AI-driven prognosis tests to assist physicians in selecting the most effective treatment for cancer patients, today announced that it has raised €6.2 million in a seed funding round. The investment was led by Kurma Partners and Heal Capital.
Spotlight Medical Emerges from Stealth to Tackle the Critical Issue of Inadequate Cancer Treatments
Spotlight Medical, spinoff of Institut Curie, proudly announced its official launch. This innovative startup aims to transform cancer treatment using advanced artificial intelligence (AI), leveraging a unique technology developed by researchers and clinicians from Institut Curie, Mines Paris – PSL, and Inserm, over several years.
